- Home
- PHAR vs VVR Comparison
PHAR vs VVR Comparison
Compare PHAR & VVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAR | VVR |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 503.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PHAR | VVR |
|---|---|---|
| Price | $17.68 | $3.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $38.00 | N/A |
| AVG Volume (30 Days) | 26.8K | ★ 692.2K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.38% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $362,274,000.00 | N/A |
| Revenue This Year | $25.19 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $3,002.99 | ★ N/A |
| Revenue Growth | ★ 26.78 | N/A |
| 52 Week Low | $7.50 | $3.55 |
| 52 Week High | $18.30 | $4.38 |
Technical Indicators
Market Signals| Indicator | PHAR | VVR |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 44.71 |
| Support Level | $16.55 | $3.25 |
| Resistance Level | $18.30 | $3.35 |
| Average True Range (ATR) | 0.80 | 0.03 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 41.02 | 50.00 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About VVR Invesco Senior Income Trust (DE)
Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide a high level of current income, consistent with the preservation of capital. The company invests in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions.